Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease

References

• Laube BL, Janssens HM, de Jongh FHC, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308–1331. doi:10.1183/09031936.00166410
   PubMed Web of Science ®Google Scholar
• Bonini M, Usmani OS. The importance of inhaler devices in the treatment of COPD. COPD Res Pract. 2015;102(1):10–19. doi:10.1016/j.rmed.2007.07.031
   Google Scholar
• Mahler DA. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. Respir Med. 2020;161:105857. doi:10.1016/j.rmed.2019.105857
   PubMed Web of Science ®Google Scholar
• Lavorini F, Fontana GA, Usmani OS. New inhaler devices - the good, the bad and the ugly. Respiration. 2014;88(1):3–15. doi:10.1159/000363390
   PubMed Web of Science ®Google Scholar
• Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft Mist™ Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl). 2011;4:145–155. doi:10.2147/MDER.S7409
   PubMedGoogle Scholar
• Dhand R, Dolovich M, Chipps B, Myers TR, Restrepo R, Farrar JR. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD. 2012;9(1):58–72. doi:10.3109/15412555.2011.630047
   PubMedGoogle Scholar
• Azouz W, Chetcuti P, Hosker HSR, Saralaya D, Chrystyn H. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study. BMC Pulm Med. 2015;15:47. doi:10.1186/s12890-015-0043-x
   PubMed Web of Science ®Google Scholar
• Ghosh S, Pleasants RA, Ohar JA, Donohue JF, Drummond MB. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:585–595. doi:10.2147/COPD.S195438
   PubMed Web of Science ®Google Scholar
• Mahler DA. Peak inspiratory flow rate: an emerging biomarker in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2019;199(12):1577–1579. doi:10.1164/rccm.201901-0005LE
   PubMed Web of Science ®Google Scholar
• Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103–1107. doi:10.1513/AnnalsATS.201702-156PS
   PubMed Web of Science ®Google Scholar
• Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers–implications for in vitro testing. J Aerosol Med. 1993;6(2):99–110. doi:10.1089/jam.1993.6.99
   PubMedGoogle Scholar
• Duarte AG, Tung L, Zhang W, Hsu ES, Kuo YF, Sharma G. Spirometry measurement of peak inspiratory flow identifies suboptimal use of dry powder inhalers in ambulatory patients with COPD. Chronic Obstruct Pulmon Dis. 2019;6(3):246–255. doi:10.15326/jcopdf.6.3.2018.0163
   PubMed Web of Science ®Google Scholar
• Benque B, Khinast JG. Understanding the motion of hard-shell capsules in dry powder inhalers. Int J Pharm. 2019;567:118481. doi:10.1016/j.ijpharm.2019.118481
   PubMed Web of Science ®Google Scholar
• Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19(1):10. doi:10.1186/s12931-017-0710-y
   PubMed Web of Science ®Google Scholar
• Broeders MEAC, Molema J, Hop WCJ, Vermue NA, Folgering HTM. The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir Med. 2004;98(12):1173–1179. doi:10.1016/j.rmed.2004.04.010
   PubMed Web of Science ®Google Scholar
• Pleasants RA. Dry powder inhalers and humidity: another factor to consider to ensure adequate lung delivery. Ann Am Thorac Soc. 2017;14(10):1602. doi:10.1513/AnnalsATS.201706-454LE
   PubMed Web of Science ®Google Scholar
• Dal Negro RW. Dry powder inhalers and the right things to remember: a concept review. Multidiscip Respir Med. 2015;10(1):13. doi:10.1186/s40248-015-0012-5
   PubMedGoogle Scholar
• Capstick TGD, Clifton IJ. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Rev Respir Med. 2012;6(1):91–101; quiz 102–103. doi:10.1586/ers.11.89
   PubMed Web of Science ®Google Scholar
• Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2017;30(6):381–387. doi:10.1089/jamp.2017.1416
   PubMed Web of Science ®Google Scholar
• Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78–83. doi:10.1183/09031936.00024807
   PubMed Web of Science ®Google Scholar
• Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26(3):174–179. doi:10.1089/jamp.2012.0987
   PubMed Web of Science ®Google Scholar
• Loh CH, Peters SP, Lovings TM, Ohar JA. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc. 2017;14(8):1305–1311. doi:10.1513/AnnalsATS.201611-903OC
   PubMed Web of Science ®Google Scholar
• Sharma G, Mahler DA, Mayorga VM, Deering KL, Harshaw O, Ganapathy V. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chron Obstruct Pulmon Dis. 2017;4(3):217–224. doi:10.15326/jcopdf.4.3.2017.0183
   PubMed Web of Science ®Google Scholar
• Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing. 2007;36(2):213–218. doi:10.1093/ageing/afl174
   PubMed Web of Science ®Google Scholar
• Sanders KJC, Kneppers AEM, van de Bool C, Langen RCJ, Schols AMWJ. Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective. J Cachexia Sarcopenia Muscle. 2016;7(1):5–22. doi:10.1002/jcsm.12062
   PubMed Web of Science ®Google Scholar
• Seheult JN, Costello S, Tee KC, et al. Investigating the relationship between peak inspiratory flow rate and volume of inhalation from a DiskusTM Inhaler and baseline spirometric parameters: a cross-sectional study. Springerplus. 2014;3:496. doi:10.1186/2193-1801-3-496
   PubMedGoogle Scholar
• Plavec D, Gluncic TJ, Gudelj I, Mise K. [Measurement of inspiratory flow for the selection of the inhalation treatment device for asthma and COPD]. Lijec Vjesn. 2012;134(3–4):84–89. Croatian.
   PubMedGoogle Scholar
• Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir Med. 2003;97(2):181–187. doi:10.1053/rmed.2003.1351
   PubMed Web of Science ®Google Scholar
• Sanders MJ. Guiding inspiratory flow: development of the In-Check DIAL G16, a tool for improving inhaler technique. Pulm Med. 2017;2017:1495867. doi:10.1155/2017/1495867
   PubMed Web of Science ®Google Scholar
• In-Check Dial. How to reset and use the In-Check DIAL: instructions. Alliance Tech Medical. Available from: http://alliancetechmedical.com/educationclinicals/. Accessed May 13, 2020.
   Google Scholar
• In-Check DIAL G16. Inhaler technique training and assessment tool. Alliance Tech Medical. Available from: http://www.alliancetechmedical.com/products/check-dial-training-device/. Accessed May 13, 2020.
   Google Scholar
• Abadelah M, Chrystyn H, Larhrib H. Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler. Eur J Pharm Sci. 2019;134:138–144. doi:10.1016/j.ejps.2019.04.018
   PubMed Web of Science ®Google Scholar
• Altman P, Wehbe L, Dederichs J, et al. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulm Med. 2018;18(1):100. doi:10.1186/s12890-018-0662-0
   PubMed Web of Science ®Google Scholar
• Pavkov R, Mueller S, Fiebich K, et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin. 2010;26(11):2527–2533. doi:10.1185/03007995.2010.518916
   PubMed Web of Science ®Google Scholar
• Prime D, de Backer W, Hamilton M, et al. Effect of disease severity in asthma and chronic obstructive pulmonary disease on inhaler-specific inhalation profiles through the ELLIPTA® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2015;28(6):486–497. doi:10.1089/jamp.2015.1224
   PubMed Web of Science ®Google Scholar
• In-Check Dial G16. Clement Clarke International. Available from: https://www.haag-streit.com/clement-clarke/products/inhaler-technique/in-check-dial-g16/. Accessed May 13, 2020.
   Google Scholar
• Drug treatments for asthma and chronic obstructive pulmonary disease that do not use chlorofluorocarbons. U.S. Food and Drug Administration. Available from: https://www.fda.gov/drugs/information-drug-class/drug-treatments-asthma-and-chronic-obstructive-pulmonary-disease-do-not-use-chlorofluorocarbons. Accessed September 7, 2021.
   Google Scholar
• FDA approved drugs in pulmonary/respiratory diseases. CenterWatch. Available from: https://www.centerwatch.com/drug-information/fda-approved-drugs/. Accessed May 13, 2019.
   Google Scholar
• Prescription and over-the-counter drug product list. 39th edition. Cumulative supplement number 01; January, 2019. Available from: https://www.fda.gov/media/124005/download. Accessed September 7, 2021.
   Google Scholar
• Serevent® Diskus® (salmeterol xinafoate) [prescribing information]. North Carolina: GlaxoSmithkline; 2018.
   Google Scholar
• Anoro™ Ellipta™ (umeclidinium and vilanterol) [prescribing information]. North Carolina: GlaxoSmithkline; 2014.
   Google Scholar
• Spiriva® HandiHaler® (tiotropium bromide) [prescribing information]. Connecticut: Boehringer Ingelheim Pharmaceuticals, Inc.; 2015.
   Google Scholar
• UtibronTM Neohaler® (indacaterol and glycopyrrolate) [prescribing information]. Massachusetts: Sunovion Pharmaceuticals Inc.; 2016.
   Google Scholar
• Tudorza® Pressair® (Aclidinium bromide) [prescribing information]. Delaware: AstraZeneca Pharmaceuticals LP; 2019.
   Google Scholar
• Proair RespiClick® (albuterol sulfate) [prescribing information]. Pennsylvania: Teva Respiratory, LLC; 2015.
   Google Scholar
• Proair® DigihalerTM (albuterol sulfate) [prescribing information]. Pennsylvania: Teva Respiratory, LLC; 2018.
   Google Scholar
• Wixela™ Inhub™ (fluticasone propionate and salmeterol) [prescribing information]. West Virginia: Mylan Pharmaceuticals Inc.; 2019.
   Google Scholar
• Alsomali HJ, Vines DL, Stein BD, Becker EA. Evaluating the effectiveness of written dry powder inhaler instructions and health literacy in subjects diagnosed with COPD. Respir Care. 2017;62(2):172–178. doi:10.4187/respcare.04686
   PubMed Web of Science ®Google Scholar
• Azouz W, Chetcuti P, Hosker HSR, Saralaya D, Stephenson J, Chrystyn H. The inhalation characteristics of patients when they use different dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2015;28(1):35–42. doi:10.1089/jamp.2013.1119
   PubMed Web of Science ®Google Scholar
• Broeders ME, Molema J, Burnell PK, Folgering HT. Ventolin Diskus and Inspyril Turbuhaler: an in vitro comparison. J Aerosol Med. 2005;18(1):74–82. doi:10.1089/jam.2005.18.74
   PubMedGoogle Scholar
• Cegla UH. Pressure and inspiratory flow characteristics of dry powder inhalers. Respir Med. 2004;98(Suppl A):S22–28. doi:10.1016/j.rmed.2004.02.003
   PubMed Web of Science ®Google Scholar
• de Koning JP, van der Mark TW, Coenegracht PMJ, Tromp TFJ, Frijlink HW. Effect of an external resistance to airflow on the inspiratory flow curve. Int J Pharm. 2002;234(1–2):257–266. doi:10.1016/S0378-5173(01)00969-3
   PubMed Web of Science ®Google Scholar
• Farkas A, Szipocs A, Horvath A, et al. Establishment of relationships between native and inhalation device specific spirometric parameters as a step towards patient tailored inhalation device selection. Respir Med. 2019;154:133–140. doi:10.1016/j.rmed.2019.06.021
   PubMed Web of Science ®Google Scholar
• Hira D, Koide H, Nakamura S, et al. Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices. PLoS One. 2018;13(2):e0193082. doi:10.1371/journal.pone.0193082
   PubMed Web of Science ®Google Scholar
• Kawamatawong T, Khiawwan S, Pornsuriyasak P. Peak inspiratory flow rate measurement by using In-Check DIAL for the different inhaler devices in elderly with obstructive airway diseases. J Asthma Allergy. 2017;10:17–21. doi:10.2147/JAA.S127580
   PubMed Web of Science ®Google Scholar
• Magnussen H, Watz H, Zimmermann I, et al. Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med. 2009;103(12):1832–1837. doi:10.1016/j.rmed.2009.07.006
   PubMed Web of Science ®Google Scholar
• Mahler DA, Ohar JA, Barnes CN, Moran EJ, Pendyala S, Crater GD. Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory flow rate. Chronic Obstruct Pulmon Dis. 2019;6(4):321–331.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Waterman LA, Ward J, Gifford AH. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. J Aerosol Med Pulm Drug Deliv. 2014;27(2):103–109. doi:10.1089/jamp.2013.1038
   PubMed Web of Science ®Google Scholar
• Malmberg LP, Everard ML, Haikarainen J, Lähelmä S. Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler®. J Aerosol Med Pulm Drug Deliv. 2014;27(5):329–340. doi:10.1089/jamp.2013.1099
   PubMed Web of Science ®Google Scholar
• Malmberg LP, Rytila P, Happonen P, Haahtela T. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int J Chron Obstruct Pulmon Dis. 2010;5:257–262. doi:10.2147/COPD.S11474
   PubMedGoogle Scholar
• Melani AS, Bracci LS, Rossi M. Reduced peak inspiratory effort through the Diskus® and the Turbuhaler® due to mishandling is common in clinical practice. Clin Drug Investig. 2005;25(8):543–549. doi:10.2165/00044011-200525080-00007
   PubMed Web of Science ®Google Scholar
• Negro RD, Micheletto C, Tognella S, Clayton N, Cantini L, Woodcock A. Evidence of adequacy of the performance of the Pulvinal by measuring through-device peak inspiratory flow rate in severe airways obstruction in adults and children. J Aerosol Med. 2001;14(3):343–349. doi:10.1089/089426801316970303
   PubMedGoogle Scholar
• Price DB, Yang S, Ming SWY, et al. Physiological predictors Of peak inspiRatory flow using Observed lung function resultS (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2018;13:3937–3946. doi:10.2147/COPD.S174371
   PubMed Web of Science ®Google Scholar
• Quinet P, Young CA, Heritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. Ann Phys Rehabil Med. 2010;53(2):69–76. doi:10.1016/j.rehab.2009.11.001
   PubMedGoogle Scholar
• Sarinas PS, Robinson TE, Clark AR, Canfield J Jr, Chitkara RK, Fick RB Jr. Inspiratory flow rate and dynamic lung function in cystic fibrosis and chronic obstructive lung diseases. Chest. 1998;114(4):988–992. doi:10.1378/chest.114.4.988
   PubMed Web of Science ®Google Scholar
• Seheult JN, O’Connell P, Tee KC, et al. The acoustic features of inhalation can be used to quantify aerosol delivery from a Diskus™ dry powder inhaler. Pharm Res. 2014;31(10):2735–2747. doi:10.1007/s11095-014-1371-x
   PubMed Web of Science ®Google Scholar
• Terzano C, Oriolo F. Lung characteristics in elderly males and females patients with COPD: differences and optimal use of dry powder inhalers (DPIs). Eur Rev Med Pharmacol Sci. 2017;21(11):2708–2716.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Weuthen T, Harmer QJ, Jones S. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study. Expert Opin Drug Deliv. 2014;11(12):1849–1857. doi:10.1517/17425247.2014.949236
   PubMed Web of Science ®Google Scholar
• Anderson M, Collison K, Drummond MB, et al. Peak inspiratory flow rate in COPD: an analysis of clinical trial and real-world data. Int J Chron Obstruct Pulmon Dis. 2021;16:933–943. doi:10.2147/COPD.S291554
   PubMed Web of Science ®Google Scholar
• Chetta A, Yorgancioglu A, Scuri M, Barile S, Guastalla D, Dekhuijzen PNR. Inspiratory flow profile and usability of the NEXThaler, a multidose dry powder inhaler, in asthma and COPD. BMC Pulm Med. 2021;21(1):65. doi:10.1186/s12890-021-01430-9
   PubMed Web of Science ®Google Scholar
• Jõgi R, Mattila L, Vahteristo M, et al. Inspiratory flow parameters through dry powder inhalers in healthy volunteers and patients with chronic obstructive pulmonary disease (COPD): device resistance does not limit use in COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:1193–1201. doi:10.2147/COPD.S298514
   PubMed Web of Science ®Google Scholar
• Malmberg LP, Pelkonen AS, Vartiainen V, Vahteristo M, Lähelmä S, Jõgi R. Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler® dry powder inhaler: a pooled analysis of two randomized controlled trials. J Thorac Dis. 2021;13(2):621–631. doi:10.21037/jtd-20-2112
   PubMed Web of Science ®Google Scholar
• Chen SY, Huang CK, Peng HC, Yu CJ, Chien JY. Inappropriate peak inspiratory flow rate with dry powder inhaler in chronic obstructive pulmonary disease. Sci Rep. 2020;10(1):7271. doi:10.1038/s41598-020-64235-6
   PubMed Web of Science ®Google Scholar
• Ding N, Zhang W, Wang Z, et al. Prevalence and associated factors of suboptimal daily peak inspiratory flow and technique misuse of dry powder inhalers in outpatients with stable chronic airway diseases. Int J Chron Obstruct Pulmon Dis. 2021;16:1913–1924. doi:10.2147/COPD.S311178
   PubMed Web of Science ®Google Scholar
• Harb HS, Laz NI, Rabea H, Abdelrahim MEA. Prevalence and predictors of suboptimal peak inspiratory flow rate in COPD patients. Eur J Pharm Sci. 2020;147:105298. doi:10.1016/j.ejps.2020.105298
   PubMed Web of Science ®Google Scholar
• Al-Showair RAM, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101(11):2395–2401. doi:10.1016/j.rmed.2007.06.008
   PubMed Web of Science ®Google Scholar
• Broeders ME, Molema J, Vermue NA, Folgering HT. Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Eur Respir J. 2001;18(5):780–783. doi:10.1183/09031936.01.00240301
   PubMed Web of Science ®Google Scholar
• Broeders MEAC, Molema J, Hop WCJ, Folgering HTM. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. J Aerosol Med. 2003;16(2):131–141. doi:10.1089/089426803321919898
   PubMedGoogle Scholar
• Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, Witek TJ Jr. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med. 2001;14(3):309–315. doi:10.1089/089426801316970268
   PubMedGoogle Scholar
• Weiner P, Weiner M. Inspiratory muscle training may increase peak inspiratory flow in chronic obstructive pulmonary disease. Respiration. 2006;73(2):151–156. doi:10.1159/000088095
   PubMed Web of Science ®Google Scholar
• Represas-Represas C, Aballe-Santos L, Fernández-García A, et al. Evaluation of suboptimal peak inspiratory flow in patients with stable COPD. J Clin Med. 2020;9(12):3949. doi:10.3390/jcm9123949
   PubMed Web of Science ®Google Scholar
• Price DB, Roman-Rodriguez M, McQueen RB, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract. 2017;5(4):1071–1081.e1079. doi:10.1016/j.jaip.2017.01.004
   PubMed Web of Science ®Google Scholar
• Sa RC, Zeman KL, Bennett WD, Prisk GK, Darquenne C. Effect of posture on regional deposition of coarse particles in the healthy human lung. J Aerosol Med Pulm Drug Deliv. 2015;28(6):423–431. doi:10.1089/jamp.2014.1189
   PubMed Web of Science ®Google Scholar
• Vytrisalova M, Hendrychova T, Touskova T, et al. Breathing out completely before inhalation: the most problematic step in application technique in patients with non-mild chronic obstructive pulmonary disease. Front Pharmacol. 2019;10:241. doi:10.3389/fphar.2019.00241
   PubMed Web of Science ®Google Scholar
• Bouhuys A. Breathing; Physiology, Environment and Lung Disease. New York: Grune & Stratton; 1974.
   Google Scholar
• Yokoyama H, Yamamura Y, Ozeki T, Iga T, Yamada Y. Analysis of relationship between peak inspiratory flow rate and amount of drug delivered to lungs following inhalation of fluticasone propionate with a Diskhaler. Biol Pharm Bull. 2007;30(1):162–164. doi:10.1248/bpb.30.162
   PubMed Web of Science ®Google Scholar
• Boshra MS, Almeldien AG, Eldin RS, et al. Inhaled salbutamol from Aerolizer and diskus at different inhalation flows, inhalation volume and number of inhalations in both healthy subjects and COPD patients. Exp Lung Res. 2019;45(3–4):84–91. doi:10.1080/01902148.2019.1621408
   PubMed Web of Science ®Google Scholar
• Boshra MS, Almeldien AG, Salah Eldin R, et al. Total emitted dose of salbutamol sulphate at different inhalation flows and inhalation volumes through different types of dry powder inhalers. Exp Lung Res. 2018;44(4–5):211–216. doi:10.1080/01902148.2018.1489015
   PubMed Web of Science ®Google Scholar
• Barnes CN, Mahler DA, Ohar JA, Lombardi DA, Crater GD. Peak inspiratory flows: defining repeatability limits and a predictive equation for different inhalers. Chest. 2020;158(4):1413–1419. doi:10.1016/j.chest.2020.03.072
   PubMed Web of Science ®Google Scholar
• Hygiene instructions for In Check and In Check DIAL. Alliance Tech Medical; April 13, 2020. Available from: https://www.alliancetechmedical.com/files/8915/7443/9937/2019_HYGIENE_INSTRUCTIONS_FOR_In_Check_and_In_Check_DIAL.pdf. Accessed April 27, 2020.
   Google Scholar
• Pulmonary function laboratories: advice regarding COVID-19. American Thoracic Society. Available from: https://www.thoracic.org/professionals/clinical-resources/disease-related-resources/pulmonary-function-laboratories.php. Accessed April 27, 2020.
   Google Scholar
• Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019;200(8):e70–e88. doi:10.1164/rccm.201908-1590ST
   PubMed Web of Science ®Google Scholar
• Culver BH, Graham BL, Coates AL, et al. Recommendations for a standardized pulmonary function report. An official American Thoracic Society technical statement. Am J Respir Crit Care Med. 2017;196(11):1463–1472. doi:10.1164/rccm.201710-1981ST
   PubMed Web of Science ®Google Scholar
• Ruppel GL, Carlin BW, Hart M, Doherty DE. Office spirometry in primary care for the diagnosis and management of COPD: national lung health education program update. Respir Care. 2018;63(2):242–252. doi:10.4187/respcare.05710
   PubMed Web of Science ®Google Scholar
• Symbicort® (budesonide and formoterol fumarate dihydrate) [prescribing information]. Delaware: AstraZeneca Pharmaceuticals LP; 2006.
   Google Scholar
• Stiolto® Respimat® (tiotropium bromide and oladeterol) [prescribing information]. Connecticut: Boehringer Ingelheim Pharmaceuticals, Inc.; 2015.
   Google Scholar